Found: 41
Select item for more details and to access through your institution.
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 730, doi. 10.1111/bjh.17385
- By:
- Publication type:
- Article
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 356, doi. 10.1111/bjh.16088
- By:
- Publication type:
- Article
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 2, p. 242, doi. 10.1111/bjh.15560
- By:
- Publication type:
- Article
<italic>MYD88</italic> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 3, p. 374, doi. 10.1111/bjh.15049
- By:
- Publication type:
- Article
Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 5, p. 808, doi. 10.1111/bjh.14103
- By:
- Publication type:
- Article
Cell‐free DNA analysis for detection of MYD88<sup>L265P</sup> and CXCR4<sup>S338X</sup> mutations in Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E250, doi. 10.1002/ajh.26184
- By:
- Publication type:
- Article
Nursing perspectives on the confusion assessment method: a qualitative focus group study.
- Published in:
- Age & Ageing, 2018, v. 47, n. 6, p. 880, doi. 10.1093/ageing/afy107
- By:
- Publication type:
- Article
Hypothyroidism: Does Treatment Cure Dementia?
- Published in:
- Journal of Geriatric Psychiatry & Neurology, 1994, v. 7, n. 1, p. 23, doi. 10.1177/089198879400700105
- By:
- Publication type:
- Article
Genetic Linkage of FcγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy.
- Published in:
- Clinical Cancer Update, 2007, v. 1, n. 1, p. 74, doi. 10.3816/CCU.2007.n.012
- By:
- Publication type:
- Article
Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 56
- By:
- Publication type:
- Article
Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 10
- By:
- Publication type:
- Article
Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 62
- By:
- Publication type:
- Article
Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 4, p. 286
- By:
- Publication type:
- Article
Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 250, doi. 10.1016/j.clml.2013.04.002
- By:
- Publication type:
- Article
Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 181, doi. 10.1016/j.clml.2013.04.001
- By:
- Publication type:
- Article
Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 241, doi. 10.1016/j.clml.2013.02.016
- By:
- Publication type:
- Article
Familial Disease Predisposition Impacts Treatment Outcome in Patients With Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 6, p. 433, doi. 10.1016/j.clml.2012.08.006
- By:
- Publication type:
- Article
Matrix Metalloproteinase-8 Is Overexpressed in Waldenström’s Macroglobulinemia Cells, and Specific Inhibition of this Metalloproteinase Blocks Release of Soluble CD27.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 172, doi. 10.3816/CLML.2011.n.041
- By:
- Publication type:
- Article
Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with Bortezomib in Waldenström's macroglobulinemia.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 133, doi. 10.3816/CLML.2011.n.030
- By:
- Publication type:
- Article
Associated Malignancies in Patients with Waldenström's Macroglobulinemia and Their Kin.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 88, doi. 10.3816/CLML.2011.n.016
- By:
- Publication type:
- Article
Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 160, doi. 10.3816/CLML.2011.n.038
- By:
- Publication type:
- Article
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 152, doi. 10.3816/CLML.2011.n.036
- By:
- Publication type:
- Article
Report From the Sixth International Workshop on Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 68, doi. 10.3816/CLML.2011.n.010
- By:
- Publication type:
- Article
Assessing assessment: evaluating geriatric technology.
- Published in:
- Canadian Medical Association Journal (CMAJ), 1993, v. 148, n. 6, p. 897
- By:
- Publication type:
- Article
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41408-020-0277-6
- By:
- Publication type:
- Article
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. E95, doi. 10.1002/ajh.25730
- By:
- Publication type:
- Article
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. 372, doi. 10.1002/ajh.25712
- By:
- Publication type:
- Article
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 2, p. 171, doi. 10.1111/bjh.12102
- By:
- Publication type:
- Article
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 3, p. 357, doi. 10.1111/j.1365-2141.2011.08750.x
- By:
- Publication type:
- Article
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 2, p. 223, doi. 10.1111/j.1365-2141.2011.08726.x
- By:
- Publication type:
- Article
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
- Published in:
- British Journal of Haematology, 2009, v. 145, n. 1, p. 59, doi. 10.1111/j.1365-2141.2009.07592.x
- By:
- Publication type:
- Article
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2008, v. 142, n. 5, p. 775, doi. 10.1111/j.1365-2141.2008.07257.x
- By:
- Publication type:
- Article
Thiamine versus placebo in older heart failure patients: study protocol for a randomized controlled crossover feasibility trial (THIAMINE-HF).
- Published in:
- Pilot & Feasibility Studies, 2018, v. 4, n. 1, p. N.PAG, doi. 10.1186/s40814-018-0342-0
- By:
- Publication type:
- Article
IN REPLY TO DRS. PARASHAR AND VARMA.
- Published in:
- 2007
- By:
- Publication type:
- Letter
ASSOCIATION BETWEEN PSYCHOTROPIC DRUG USE AND HEART FAILURE THERAPY IN ELDERLY LONG-TERM CARE RESIDENTS.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Nodding and napping in medical lectures: an instructive systematic review.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Incidence of and risk factors for nodding off at scientific sessions.
- Published in:
- Canadian Medical Association Journal (CMAJ), 2004, v. 171, n. 12, p. 1443, doi. 10.1503/cmaj.1041570
- By:
- Publication type:
- Article